APPLICATION NUMBER:
22-071

APPROVAL LETTER
NDA 22-071

Novartis Pharmaceuticals Corporation
Attention: Paula Rinaldi
Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Ms. Rinaldi:

Please refer to your new drug application (NDA) dated September 8, 2006, received September 8, 2006, submitted pursuant to section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act for LAMISIL (terbinafine hydrochloride) Oral Granules, 125 mg & 187.5 mg.

We acknowledge receipt of your submissions dated November 2 & 8; December 1, 4 & 5, 2006; January 8, 22; February 5; March 9, 20, 29, & 30; May 8, 18 & 24; June 18 and July 25, 2007.

This new drug application provides for the use of LAMISIL (terbinafine hydrochloride) Oral Granules, 125 mg & 187.5 mg, for the indication of tinea capitis in patients 4 years of age and older.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 22-071.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PEDIATRIC RESEARCH EQUITY ACT (PREA)

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and
effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

Please submit one market package of the drug product when it is available.

If you have any questions, please call Kalyani Bhatt, Regulatory Project Manager, at (301) 796-2110.

Sincerely,

[See appended electronic signature page]

Susan J. Walker, M.D., FAAD
Director
Division of Dermatology and Dental Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

Appears This Way
On Original
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Susan Walker
9/28/2007 04:18:32 PM
Concur with medical officer and team leader recommendations.

Appears This Way
On Original